Literature DB >> 18439106

BRCA2 gene mutations in Slovenian male breast cancer patients.

Nikola Besic1, Barabara Cernivc, Jacques de Grève, Katarina Lokar, Mateja Krajc, Srdan Novakovic, Janez Zgajnar, Erik Teugels.   

Abstract

Male breast cancer (MBC) is a rare disease, comprising less than 1% of breast cancer patients in Slovenia. Some inherited cases are due to the mutations of BRCA1 or BRCA2 genes. There is no information available about the frequency of BRCA gene mutations in Slovenian MBC population. The purpose of this study was to characterize BRCA germline mutations in Slovenian MBC patients. Forty-one patients who were diagnosed with breast cancer at the Institute of Oncology Ljubljana between 1970 and 2006 were proposed to take part in this study. Of them, 27 agreed to follow a genetic counseling session and 25 patients agreed to provide a blood sample for genetic testing. The BRCA1 and BRCA2 genes from the MBC patients were screened for four highly recurrent mutations in the Slovenian population. When an additional breast cancer case or an ovarian cancer was present in the family, a more extended analysis was performed. No BRCA1 mutations were found. A BRCA2 gene mutation was identified in four MBC patients. Three of them carried the Slovenian founder mutation IVS16-2A>G. All four mutations were confined to the patients with a family history of breast cancer. Among the MBC patients with a family history of breast cancer in the first- or second-degree relatives, the frequency of BRCA2 gene mutation was 50%. The median age of the patients with a BRCA2 gene mutation was 60 years, not significantly different from those without a mutation. The BRCA2 mutations were diagnosed in 16% of our MBC patients.

Entities:  

Mesh:

Year:  2008        PMID: 18439106     DOI: 10.1089/gte.2007.0071

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  9 in total

1.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.

Authors:  Yuan Chun Ding; Linda Steele; Chih-Jen Kuan; Scott Greilac; Susan L Neuhausen
Journal:  Breast Cancer Res Treat       Date:  2010-10-07       Impact factor: 4.872

Review 2.  Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.

Authors:  Furu Wang; Qiaoqiao Fang; Zhen Ge; Ningle Yu; Sanxiao Xu; Xiangyong Fan
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

3.  Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.

Authors:  Ksenija Strojnik; Mateja Krajc; Vita Setrajcic Dragos; Vida Stegel; Srdjan Novakovic; Ana Blatnik
Journal:  Breast Cancer Res Treat       Date:  2021-04-23       Impact factor: 4.872

4.  The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population.

Authors:  Vida Stegel; Mateja Krajc; Janez Zgajnar; Erik Teugels; Jacques De Grève; Marko Hočevar; Srdjan Novaković
Journal:  BMC Med Genet       Date:  2011-01-14       Impact factor: 2.103

Review 5.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

6.  Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.

Authors:  Pedro Pinto; Ana Peixoto; Catarina Santos; Patrícia Rocha; Carla Pinto; Manuela Pinheiro; Luís Leça; Ana Teresa Martins; Verónica Ferreira; Carla Bartosch; Manuel R Teixeira
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

7.  Genetic Counselling, BRCA1/2 Status and Clinico-pathologic Characteristics of Patients with Ovarian Cancer before 50 Years of Age.

Authors:  Mirjam Cvelbar; Marko Hocevar; Srdjan Novakovic; Vida Stegel; Andraz Perhavec; Mateja Krajc
Journal:  Radiol Oncol       Date:  2017-03-16       Impact factor: 2.991

8.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

Authors:  Oubaida ElBiad; Abdelilah Laraqui; Fatima El Boukhrissi; Chaimaa Mounjid; Maryame Lamsisi; Tahar Bajjou; Hicham Elannaz; Amine Idriss Lahlou; Jaouad Kouach; Khadija Benchekroune; Mohammed Oukabli; Hafsa Chahdi; Moulay Mustapha Ennaji; Rachid Tanz; Yassir Sbitti; Mohammed Ichou; Khalid Ennibi; Bouabid Badaoui; Yassine Sekhsokh
Journal:  BMC Cancer       Date:  2022-02-25       Impact factor: 4.430

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.